Dulaglutide

• CAT Number: I046317
• CAS Number: 923950-08-7
• Purity: ≥95%

Dulaglutide (Cat No.: I046317) is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes mellitus. It mimics endogenous GLP-1, stimulating insulin secretion, suppressing glucagon release, and slowing gastric emptying, thereby improving blood glucose control. Administered once weekly via subcutaneous injection, dulaglutide also supports weight loss and cardiovascular risk reduction. It is generally well-tolerated, with common side effects including nausea, vomiting, and diarrhea. Dulaglutide should be used cautiously in patients with a history of pancreatitis or medullary thyroid carcinoma.

Reference

[1]. Chang W, et al. Glucagon-like peptide-1 receptor agonist dulaglutide prevents ox-LDL-induced adhesion of monocytes to human endothelial cells: An implication in the treatment of atherosclerosis. Mol Immunol. 2019 Dec;116:73-79.
[Content Brief]

[2]. Hertzel C Gerstein, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet
[Content Brief]

[3]. Byrd RA, et al. Chronic Toxicity and Carcinogenicity Studies of the Long-Acting GLP-1 Receptor AgonistDulaglutide in Rodents. Endocrinology. 2015 Jul;156(7):2417-28.
[Content Brief]